Skip to main content
. 2018 May 10;18:65. doi: 10.1186/s12905-018-0555-7

Table 3.

Least squares (LS) means scoresa (95% Confidence intervals, CIs) of HRQoL according to quartiles of Healthy dietary pattern in breast cancer survivors

Quartiles of the Healthy dietary pattern
Variables N (=232) Quartile 1 Quartile 2 Quartile 3 Quartile 4 P for trend
EORTC QLQ - C30
 Global health status/QoL 220 40.41 (28.37 - 57.55) 37.47 (27.10 - 51.81) 39.93 (28.92 - 55.14) 30.00 (20.83 - 43.21) 0.31
Functioning
 Physical Functioning 228 76.21 (67.82 - 85.65) 79.02 (71.09 - 87.85) 77.80 (69.85 - 86.65) 71.45 (63.52 - 80.37) 0.45
 Role Functioning 229 62.82 (49.32 - 80.02) 77.50 (61.80- 97.17) 69.47 (55.05 - 87.66) 65.77 (51.12 - 84.62) 0.84
 Emotional Functioning 230 76.24 (63.16 - 92.04) 72.09 (60.45 - 85.96) 60.42 (50.51 - 72.26) 71.77 (58.99 - 87.32) 0.31
 Cognitive Functioning 230 74.53 (65.00 - 85.44) 78.52 (69.10 - 89.22) 73.09 (64.18 - 83.23) 70.66 (61.28 - 81.47) 0.48
 Social Functioning 230 57.8 (45.69 - 73.12) 63.28 (50.80 - 78.84) 60.55 (48.42 - 75.72) 62.67 (49.05 - 80.05) 0.66
Symptom
 Fatigue 229 27.26 (19.48 - 38.15) 20.26 (14.88 - 27.58) 22.61 (16.52 - 30.94) 23.51 (16.68 - 33.13) 0.55
 Nausea and vomiting 230 4.00 (2.48 - 6.44) 2.24 (1.44 - 3.49) 3.71 (2.36 - 5.83) 3.17 (1.93 - 5.21) 0.73
 Pain 229 9.84 (5.80 - 16.71) 6.13 (3.77 - 9.97) 11.13 (6.79 - 18.24) 10.64 (6.20 - 18.28) 0.53
 Dyspneab,c 228 8.86 (5.05 - 15.52) 4.21 (2.52 - 7.03) 4.75 (2.82 - 8.01) 2.87 (1.62 - 5.08) 0.005
 Insomniab,c 228 11.46 (6.59 - 19.95) 12.11 (7.28 - 20.15) 20.41 (12.15 - 34.26) 29.77 (16.87 - 52.51) 0.005
 Loss of appetite 228 3.00 (1.74 - 5.15) 3.66 (2.23 - 6.02) 2.65 (1.60 - 4.39) 3.32 (1.91 - 5.79) 0.99
 Constipation 228 4.25 (2.40 - 7.54) 5.69 (3.36 - 9.63) 7.01 (4.10 - 11.99) 4.18 (2.32 - 7.50) 0.78
 Diarrhea 230 3.04 (1.82 - 5.08) 2.47 (1.53 - 3.99) 2.76 (1.70 - 4.51) 1.79 (1.05 - 3.05) 0.18
 Financial impact 230 7.34 (4.12 - 13.07) 4.51 (2.63 - 7.74) 9.47 (5.47 - 16.40) 9.61 (5.27 - 17.53) 0.27
EORTC QLQ-BR23
 Functioning
  Body image 229 40.11 (27.32 - 58.88) 33.23 (23.21 - 47.59) 40.56 (28.06 - 58.62) 28.18 (18.89 - 42.03) 0.30
  Sexual functioning 216 2.83 (1.62 - 4.92) 3.89 (2.32 - 6.52) 3.93 (2.33 - 6.65) 3.94 (2.20 - 7.08) 0.33
  Future perspective 229 26.93 (15.91 - 45.58) 20.85 (12.74 - 34.10) 21.67 (13.08 - 35.90) 15.43 (8.92 - 26.70) 0.14
 Symptom
  Systematic therapy side effects 230 23.34 (17.37 - 31.37) 15.01 (11.39 - 19.79) 22.47 (16.96 - 29.76) 25.97 (19.09 - 35.33) 0.39
  Breast symptoms 230 12.10 (7.66 - 19.11) 6.96 (4.54 - 10.68) 10.50 (6.80 - 16.22) 12.11 (7.52 - 19.49) 0.84
  Arm symptoms 230 20.54 (13.59 - 31.03) 18.25 (12.41 - 26.84) 21.70 (14.65 - 32.12) 31.48 (20.48 - 48.39) 0.13
  Upset by hair loss 151 14.15 (6.70 - 29.89) 32.78 (15.61 - 68.82) 23.84 (12.30 - 46.18) 34.49 (16.45 - 72.32) 0.11

LS means least squares means, 95% CI 95% confidence interval, HRQoL health-related quality of life, EORTC QLQ-C30 European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30, BR23 breast cancer module 23

aAdjusted for age at diagnosis (year; continuous), body mass index at diagnosis (kg/m2; continuous), energy intake (kcal/d; continuous), marital status (married or cohabitation, others), education level (high school or below, college or above), physical activity (MET-hr/wk.; continuous), breast cancer stage at diagnosis (I,II,III), time since surgery (months; continuous) and menopausal status at diagnosis (premenopausal, postmenopausal status)

bP value for comparing top with bottom quintiles < 0.05

cFalse Discovery Rate (FDR) < 0.1